All Oncology News

The OncLive® News page includes the latest in clinical oncology news, including breaking regulatory decisions, clinical trial findings, pivotal and practice-changing data published in academic peer-reviewed journals, and more across solid and hematologic malignancies. Regulatory news includes new drug approvals by the FDA and European Union, priority review and breakthrough therapy designations, and orphan drug and fast track statuses.

Cilta-Cel Boosts Survival Vs SOC Across Key Subgroups of R/R Multiple Myeloma

June 1st 2025

CARTITUDE-4 subgroup data further support cilta-cel’s positive benefit-risk profile in relapsed/refractory multiple myeloma.

Sevabertinib Induces Durable Response in Advanced HER2-Mutant NSCLC

June 1st 2025

Treatment with the oral TKI showed promising responses among 2 subgroups of patients with advanced, HER2-mutant non–small cell lung cancer.

Nivolumab Plus Relatlimab Penetrates Blood-Brain Barrier in PD-(L)1-Refractory Melanoma With Brain Metastases

June 1st 2025

Nivolumab plus relatlimab generated favorable intracranial responses in patients with advanced PD-(L)1-refractory melanoma with brain metastases.

Indirect Comparisons Shows Relatlimab/Nivolumab Has Comparable Outcomes to Ipilimumab/Nivolumab in Advanced Melanoma

June 1st 2025

The efficacy of relatlimab/nivolumab was consistent across patient subgroups vs ipilimumab/nivolumab in advanced melanoma.

Sintilimab/Chidamide Plus P-GemOx Shows Antitumor Activity in Treatment-Naive, Early-Stage Natural Killer/T-Cell Lymphoma

June 1st 2025

Sintilimab/chidamide followed by P-GemOx demonstrated preliminary efficacy in treatment-naive, early-stage extranodal natural killer/T-cell lymphoma.

Adagrasib Plus Pembrolizumab Generates Responses in KRAS G12C+ NSCLC

June 1st 2025

Adagrasib plus pembrolizumab was efficacious in patients with KRAS G12C-mutant NSCLC.

Preoperative PAXG Extends EFS in Resectable and Borderline Resectable Pancreatic Cancer

June 1st 2025

Neoadjuvant therapy with PAXG chemotherapy prolonged event-free survival vs mFOLFIRINOX in patients with stage I to III pancreatic ductal adenocarcinoma.

Adjuvant Nivolumab Generates Long-Term DFS Benefit in Resected Esophageal/GEJ Cancer

June 1st 2025

Adjuvant nivolumab generated durable DFS and DMFS outcomes in resectable esophageal or GEJ cancer.

Addition of TTFields to Gemcitabine/Nab-Paclitaxel Boosts OS in Locally Advanced PDAC

June 1st 2025

TTFields plus chemotherapy improved overall survival in unresectable, locally advanced pancreatic ductal adenocarcinoma.

Adjuvant Atezolizumab Plus mFOLFOX6 Improves DFS in dMMR Colon Cancer

June 1st 2025

Adjuvant atezolizumab plus mFOLFOX6 improved disease-free survival vs mFOLFOX6 alone in patients with stage III, mismatch repair–deficient colon cancer.

Early Switch With Camizestrant Plus Continued CDK4/6 Inhibition Nearly Doubles PFS in ESR1-Mutant, ER+/HER2– Advanced Breast Cancer

June 1st 2025

Emergent ESR1-mutant, ER-positive, HER2-negative advanced breast cancer was best treated with camizestrant and continued CDK4/6 inhibition vs SOC therapy.

Perioperative Durvalumab Plus FLOT Represents New SOC in Resectable Gastric/GEJ Adenocarcinoma

June 1st 2025

The addition of durvalumab to perioperative FLOT improved event-free survival in resectable gastric/GEJ adenocarcinoma.

Postoperative Nivolumab Plus SOC Extends DFS in Resected, High-Risk Head and Neck Cancer

June 1st 2025

Patients with locally advanced, high-risk head and neck cancer showed significantly improved DFS with adjuvant nivolumab plus cisplatin and radiotherapy.

NAPOLI-3 Analysis Exposes Characteristics of Long-Term PDAC Survivors Treated With NALIRIFOX

June 1st 2025

A post hoc analysis of NAPOLI-3 reveals insights on long-term survivors with pancreatic cancer who received NALIRIFOX.

First-Line Fruquintinib Combo May Offer New Treatment Strategy in ESCC

June 1st 2025

A fruquintinib regimen appeared safe and effective when used as a frontline treatment in esophageal squamous cell carcinoma.

T-DXd Maintains Efficacy in HR+/HER2-Low or HER2-Ultralow Breast Cancer Irrespective of Mutational Subtype

June 1st 2025

T-DXd maintained efficacy in HR-positive, HER2-low or -ultralow metastatic breast cancer irrespective of mutational subtype.

Ipatasertib Plus Fulvestrant Demonstrates Significant PFS Benefit in ER+/HER2– Metastatic Breast Cancer

May 31st 2025

Ipatasertib plus fulvestrant extended PFS vs placebo plus fulvestrant in patients with ER-positive/HER2-negative metastatic breast cancer.

Sasanlimab Plus BCG Displays EFS Benefit Across Key Subgroups in High-Risk Non–Muscle Invasive Bladder Cancer

May 31st 2025

Sasanlimab plus BCG led to a PFS benefit vs BCG alone in patients with CIS and T1 high-risk non–muscle invasive bladder cancer.

Amivantamab Plus Chemo Maintains PFS Benefit in EGFR+ NSCLC Regardless of Osimertinib Resistance Mechanism

May 31st 2025

Amivantamab/chemotherapy demonstrated sustained efficacy, despite the osimertinib resistance mechanism in patients with EGFR-mutated NSCLC.

Zanubrutinib Plus Venetoclax Yields High Response Rates in Treatment-Naive CLL/SLL

May 31st 2025

Zanubrutinib in combination with venetoclax was highly active in patients with untreated chronic lymphocytic leukemia or small lymphocytic lymphoma.